Physician-scientist-led careTrinidad & Tobago +
Prenatal & reproductive

Non-Invasive Prenatal Screening (NIPT)

Maternal blood screening from 10 weeks of pregnancy for selected chromosome conditions, with core and additional screening options.

Understanding the test

Information for your pregnancy.

NIPT uses cell-free DNA in maternal blood to estimate the chance of selected chromosome conditions. Core screening covers trisomies 21, 18 and 13. Sex chromosome screening, 22q11.2 deletion screening and optional fetal sex reporting can be discussed during consultation. The selected screening scope and pregnancy circumstances guide interpretation. NIPT is a screening test; a high-risk result requires diagnostic confirmation.

How it is analysed

Next-generation sequencing of cell-free DNA from maternal blood, with chromosome-level analysis and fetal-fraction reporting.

What is included

Screening options.

NIPT assesses selected chromosome findings rather than a fixed list of individual genes. The core targets and additional options are listed below.

Core screening

Trisomy 21

Chromosome 21; associated with Down syndrome.

Trisomy 18

Chromosome 18; associated with Edwards syndrome.

Trisomy 13

Chromosome 13; associated with Patau syndrome.

Additional screening

Monosomy X

An X-chromosome copy-number finding; discuss sex chromosome screening separately.

Sex chromosome trisomies

Additional sex chromosome screening. Ask which specific findings are included in the selected test.

Expanded screening

22q11.2 deletion

A selected chromosome 22 microdeletion target; discuss the value and limitations of expanded screening.

Additional microdeletions

Discuss available additional targets, their limitations and the exact screening scope during consultation.

Optional reporting

Fetal sex

Optional reporting where requested and appropriate to the pregnancy.

In clinical context

Understanding the scope.

Choosing a test means considering both the genes or regions examined and the types of changes it can detect.

Prenatal screening guidance
  • Core screening covers trisomies 21, 18 and 13. Additional sex chromosome and microdeletion screening should be discussed separately with a clinician.
  • High-risk results should be confirmed with diagnostic testing such as CVS or amniocentesis. A low-risk result does not exclude all genetic conditions.
  • This assay does not assess single-gene disorders, small sequence variants or repeat expansions. Pregnancy circumstances and fetal fraction affect interpretation.
  • Routine microdeletion screening is not recommended for the general obstetric population. Discuss the benefits, limitations and exact targets before selecting expanded screening.

Your next step

Discuss this test
with Genomika.

We’ll discuss the clinical question and confirm testing arrangements, sample requirements, costs and reporting times.

Enquire about this test
← Back to all tests and panels

Website privacy

Your information.

The general enquiry form prepares an email in your own email application. Form entries are not submitted to a website database or stored in your browser by this site.

If you choose to send an email, the information is handled by your email provider and received by Genomika at the displayed email address. This form is intended for general enquiries only; please do not send medical records or sensitive health information through it.

This website does not add analytics or marketing cookies. The hosting service may process technical information needed to serve the site and manage access. Please contact Genomika to discuss an appropriate route for sharing clinical information.